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Age  1.  < 55 years     2. ≥  55 years
Menopause  1. attained  2. not attained
Histology 1. Serous Papillary  2. Others
Ascities  1. ≥ 500 ml   2. <  500 ml  
Residual Tumer volume  1.  Optimal  debulking  2.  
Sub Optimal debulking 3.Open and Close
Blood Transfusion   1. No transfusion  2. One  
Unit given  3. Two  units given
Adhesions  1. Present 2. Absent
Injury to adjacent  Structure  1. Present 2. Absent
HDU Stay  1. Present  2.Absent
Post op complications 1.Present  2. Absent
Duration of Hospital Stay  1. < 10 days  2. ≥  10 days
PDS Primary Debulking Surgery 
NACT  Neoadjuvant 
Chemotherapy IDS Interval  Debulking 
Surgery
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INTRODUCTION
Ovarian  tumors  are  one  of  the  most  common  gynecological 
malignancy  in  India.   It  is  the  leading  cause  of  death  from 
malignancies  arising  in  female  genital  tract.  Patients  with ovarian 
tumors are often symptom free for a long time. By the time ovarian 
malignancy is diagnosed, about 2/3 rd of these have already become 
far advanced and the prognosis in such cases is unfavourable.
Patients  with  advanced  ovarian  cancer  should  be  treated  by 
radical debulking surgery aiming at  complete tumor resection.  But 
70%  of  the  patients  present  with  advanced  disease  optimal 
debulking  cannot  be  obtained  due  to  multifactorial  reasons  like 
biological  aggressiveness  of  tumors,  coexisting  medical  problem 
and  experience  of  surgeon.  Many  trials  proved  that  giving 
neoadjuvant  chemotherapy  and  post  chemotherapy  debulking  had 
significant  improvement  in  progression  free  interval  and  overall 
survival. It also permits a less aggressive surgery to be performed.  
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Incidence:
Overall,  Ovarian  cancers  account  for  5%  of  all  cancer 
diagnosis.  The  lifetime  risk  of  ovarian  cancer  is  approximately 
1.7%. Vast  majority of   epithelial  ovarian carcinoma diagnosed in 
postmenopausal women with median age of 63 years.
Incidence  of  ovarian  cancer  in  India  is  7/100,000.In  India, 
ovarian cancer rank 6 th most common cancer in women. The ovary 
after  uterus  is  the  second  common  site  for  development  of 
gynaecological malignancy.
Pathogenesis:
          Common epithelial tumours accounts for 80%  of  all ovarian 
neoplasm. The remaining tumours arise from ovarian germ cells or 
stromal cells. The epithelial tumours arise from surface epithelium 
or  serosa  of  ovary.  Serous  carcinoma  can  resemble  the  fallopian 
tube, mucinous tumour the endocervix and endometroid carcinoma 
the endometrium. In majority of causes malignant epithelial ovarian 
tumours  disseminate  through  out  the  peritoneal  cavity  after 
exfoliation of malignant cells from the surface of the ovary.
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The  typical  circulation  of  peritoneal  fluid  along  the  under 
surface  of  the  right  hemidiaphragm  facilitates  the  frequently 
observed  pattern  of  wide  spread  dissemination  of  malignant  cells 
within  the  peritoneal  cavity.  In  addition  omentum  frequently 
attracts  these  malignant  cells  and  is  thus  a  common  site  of 
metastasis.
Tumour  spread also occur  via  lymphatics  from the ovary.  A 
primary source of drainage follows the ovarian blood supply in the 
infundibulopelvic   ligament  to  lymph  node  around  the  aorta  and 
venacava  to  the  level  of  renal  vessel.  There  is  also  lymphatic 
drainage  through  the  broad  ligament  and  parametrial  channels. 
Consequently  pelvic  side  wall  lymphatics  including  external  ilac, 
obturator,  hypogastric  chains  are  also  frequently  involved.  More 
rarely spread occur along the course of round ligament resulting in 
involvement of inguinal lymph node. Approximately 10% of patient 
with ovarian cancers that appears to be localised to the ovaries have 
metastasis to paraaortic lymph nodes.
There can also be direct extension from the ovary to involve 
adjacent peritoneal surfaces of the bladder, rectosigmoid and pelvic 
peritoneum.
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Histological classification of ovarian tumour 
1. Common epithelial tumours:
· Serous tumours
· Mucinous tumours
· Endometrioid tumours
· Clear cell(mesonephroid tumours)
· Brenner tumours
· Mixed epithelial tumours
· Undiffentiated tumours
· Unclassified epithelial tumours
11.  Sex cord (gonadal stromal) tumours:
· Granulosa-stromal cell tumours, theca cell tumours.
· Androblastomas:Stertoli-leydig cell tumours.
· Gynandroblastomas
· Unclassified.
         III.    Lipoid cell tumours
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         1V.  Germ cell tumours
· Dysgerminoma
· Endodermal sinus tumours
· Polyembryoma
· Choriocarcinoma
· Teratoma
· Mixed forms
V. Gonadoblastoma
· Pure
· Mixed with dysgerminoma or other germ cell tumour
VI. Soft tissue tumours not specific to ovary
VII. Unclassified tumours
      VIII.    Secondary (metastatic) tumours
IX. Tumour-like conditions.
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Diagnosis and management:
Epithelial cancers of ovary has been described as silent killers 
because  overwhelming  majority  of  patients  do  not  present  with 
symptoms  until  disease  has  spread  outside  the  ovary  and  indeed 
outside  pelvis  .However  many  studies  surveying  ovarian  cancer 
patient  have  demonstrated  that  95%  of  these  women  have  non 
specific  abdominal   symptoms  many  months  before  diagnosis.
Approximately  70%   of  patients  with  epithelial  ovarian 
cancers present with stage III  or stage IV  disease.
Abdominal  discomfort  and  bloating  are  the  most  common 
symptoms  experienced  by  women  with  epithelial  ovarian  cancers 
followed  by  vaginal  bleeding,  gastrointestinal  symptoms, 
genitourinary symptoms.
Patients  presenting  with  nonspecific  lower  abdominal 
discomfort  and  bloating  require  atleast  prompt  and  careful 
evaluation of pelvic and recto vaginal examination.
The most common physical signs are ascites and pelvic mass
        Level  of  cancer  antigen  (CA-125)  tumour   biomarker  is  
elevated in more than 80% of serous epithelial tumours, but it can 
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also be elevated in variety of benign conditions and in other  non-
gynaecological malignancies.
        Furthermore in early stage ovarian cancer, CA-125 levels are 
elevated in less than half of cases. Other markers such as CA-19-9 
and carcinoembryonic antigen are less frequently used.
         Pre operatively tumour marker levels are useful n predicting 
the  possibility  of  malignancy.  During  treatment  for  ovarian 
carcinoma,                CA-125 level  is  very  useful  parameter  of  
disease  activity  and  can  also  be  used  to  follow  response  to 
treatment  and to detect  an early recurrence.  Chest  radiographs are 
routinely performed to look for malignant effusion. 
Trans vaginal sonography and abdominal ultrasonography are 
the most  useful  diagnostic examination in the evaluation of pelvic 
mass   because  of  their  ability  to  accurately  discern  the  ovarian 
morphology  and  pelvic  pathology.  Some  sonographic  characters 
associated  with  ovarian  cancers  include  irregular  ovarian  border, 
solid  elements  within  the  cyst,  papillary  projection,  bilateral 
ovarian enlargement and presence of ascites.
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          Colour Doppler imaging  evaluates blood flow to an ovarian 
mass and identify a malignant process in the presence of  abnormal 
vascularisation.
          Cross sectional imaging such as computed tomography and 
magnetic  resonance  imaging  may  be  helpful  in  characterising  the 
liver,  identifying  lymph  node  involvement,  peritoneal  studding, 
omental caking and involvement of mesentery of the bowel.
           The role of positron emission tomography in preoperative 
evaluation  for  suspected  recurrent   ovarian  carcinoma  is  being 
studied in many centres.
            Diagnostic  laparoscopy  may  be  extremely  useful   to 
evaluate  unexplained  pelvic  pain  or  adnexal  mass  of  uncertain 
pathology.
STAGING
            Ovarian  cancer  staging  is  done  surgically.  Thus  it  is  
important  for  physician  to  be  thoroughly  familiar  with  the 
International  Federation  of  Gynaecology  and  Obstetrics  staging 
system for primary carcinoma of ovary.
Stage 1            Tumour restricted to one or both ovaries
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 1A         Tumour  restricted  to  one  ovary.No  tumour  on 
external 
surface. Capsule intact. No malignant ascites.
 1B              Tumour  limited  to  both  ovaries.  No  tumour  on 
external  
surface. Capsule intact. No malignant ascites.
1C         Tumour 1A or 1B, positive for surface  malignant 
growth, capsule  ruptured, malignant ascites or 
positive washings.
Stage 11 Tumour involves one / both ovaries with pelvic 
extension
11A           Extension / metastasis to uterus,or and tubes
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11B             Extension  to  other  pelvic  organs.  No  malignant 
cells in 
ascites or washings.
11 C         Tumour 11A or 11B with surface growth, capsule 
ruptured at / or prior to surgery, malignant ascites 
or 
positive washings
Stage 111 Tumour  involving  one/  both  ovaries  with 
microscopic 
implants outside the pelvis and / or positive nodes 
(inguinal, retroperitoneal). Tumour limited to true 
pelvis but with histological evidence of spread to 
bowel,  omentum,  presence  of  superficial 
metastasis on the liver
111A        Tumour  grossly  limited  to  the  pelvis,  nodes 
negative, 
but microscopic   seeding of peritoneum of the 
abdominal wall
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111B      Tumour  with  abdominal  peritoneal  implants  of 
less 
than 2 cm size and nodes negative
111C Abdominal implants of more than 2 cm size and / 
or 
positive nodes
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Stage 1V  Growth involving one or both ovaries with distant 
metastasis in liver, lungs and pleura
Complete surgical staging is a necessity to properly evaluate the 
patient  and  to  determine  whether  additional  therapy  should  be 
recommended.
Proper  surgical  staging  requires  thorough  and  complete 
inspection  of  the  peritoneal  cavity  and  its  content  as  well  as 
evaluation of the retroperitoneal space and lymph nodes. When the 
peritoneal cavity is entered,  any fluid present  should be aspirated 
and sent for cytological studies.  Peritoneal fluid even if limited to 
the pelvis is more likely to yield  malignant cells.
If no fluid is present, however one should routinely irrigate the 
pelvis  and  paracolic  gutter  and  sent  for  cytologic  examination. 
Adhesions should be lysed to restore normal anatomy and samples 
of adhesions should be sent for pathological examination.
If  peritoneal  carcinomatosis  is  not  present,  it  may  be  most 
appropriate first to resect ovarian tumour and then to proceed with 
surgical staging to help avoid rupturing of the mass.
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For  women  who  desire  future  fertility  when  the  tumour  is 
limited  to  one  ovary,  staging  may  be  completed  without 
hysterectomy  and  complete  castraction.  The  grossly  normal 
opposite  ovary  may  undergo biopsy,  any visible  benign appearing 
cyst may be excised. Preservation of fertility should be considered 
in any women of reproductive age with either borderline malignant 
tumour of the ovary or invasive epithelial  cancer grossly confined 
to one ovary.
To fully assess and resect  disease in the upper abdomen, it  is 
frequently  necessary  to  extend  the  vertical  incision  above  the 
umbilicus.If  gross  disease  is  not  present  in  the  omentum,  an 
infracolic omentectomy is sufficient for diagnostic purpose.
When  omentum  is  caked  with  tumour,  omentum  should  be 
excised  from  the  greater  curvature  of  the  stomach.  Right 
hemidiaphragm,  liver,  serosa  and  parenchyma,  spleen,  left 
hemidiaphragm are carefully inspected.
The  paracolic  gutter  space,  large  bowel,  small  bowel  and 
mesentery  are  evaluated  any  implants  present  are  removed.  If 
tumour is involving small  or large bowel transluminally,  resection 
and reanastomosis  should be performed.
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In  postmenopausal  women,  one  should  perform  Bilateral 
Salpingo-oopherectomy and Total  Abdominal  Hysterectomy at  the 
time  of  staging.  Hysterectomy  is  performed  because  the  serosal 
surface of the uterus is large peritoneal surface for implantation of  
malignant cells.
PROGNOSTIC FACTORS
At the conclusion of comprehensive laparotomy, the following 
clinical and pathological findings are used to assess prognosis and 
to select appropriate postoperative therapy.
Clinicopathological prognostic parameters
1. FIGO Staging
2. Histological sub-type
3. Histologocal grade
4. Factors associated with dissemination
5. Malignant ascites or malignant peritoneal washings
6. Tumor  excrescences  on  ovarian  surface  or  ruptured 
capsule
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7. Volume  of  residual  tumour  after  cytoreductive 
surgery
5 YEARS SURVIVAL RATE
1. Stage 1          –  76 to 93%
2. Stage 11        –  60 to 74%
3. Stage 111A   – 41%
111 B  – 25%
111 C  – 23%
4. Stage 1V       – 11%
TREATMENT OF ADVANCED OVARIAN CANCER:
The recommended treatment for patients with advanced stage 
ovarian  cancer  (111,  1V)  is  optimal  cytoreductive  surgery  to 
remove all visible tumour followed by Platinum and Taxane based 
chemotherapy.  Patients  with  advanced  stage  disease  present  in  a 
malnourished  performance  status.  Aggressive  debulking  surgery 
may  not  be  well  tolerated.  They  are  potential  high post  operative 
morbidity and mortality. Post operative complications can delay in 
starting adjuvant chemotherapy. Giving neo adjuvant chemotherapy 
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in  these  patients  prior  to  surgery  produces  reduction  in  tumour 
volume,  allow  a  less  extensive  surgery,  hence  decreasing 
perioperative   morbidity,  finally  improving  better  prognosis  and 
survival.
PRIMARY CYTOREDUCTIVE SURGERY (DEBULKING)
Standard  treatment  of  advanced  ovarian  carcinoma  includes 
primary cytoreductive surgery followed by chemotherapy.
Primary  cytoreductive  surgery  represents  the  cornerstone  in 
the  treatment  of  ovarian  cancer.  It  aims  at  removing  as  much 
primary  and  metastatic  disease  as  possible,  in  order  to  facilitate 
response to subsequent chemotherapy  and to improve survival.
Debulking  surgery  includes  Total  Abdominal  Hysterectomy 
with Bilateral and Salpingo-Oopherectomy and Omentectomy with 
or  without  lymphadenectomy.  The  definition  of  optimal 
cytoreduction  has  been  changed  many  times  in  the  last  20  years 
from  a  residual  mass  of  2  cm  to  complete  absence  of  residual 
tumour.
Despite  the  controversies   in  the  definition  of  optimal 
cytoreduction  all  investigators  do  agree  that  who fails  to  undergo 
optimal debulking have poorer prognosis.
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Patients with extensive metastatic disease before cytoreduction 
or  with  clinically  evident  ascites  had  poor  prognosis  even  if  the 
patient was cytoreduced to an optimal status.
Complications of Primary cytoreductive surgery
1. Wound infection / Dehiscence
2. Cardiac failure
3. Deep vein thrombosis
4. Pulmonary embolism
5. Genitourinary fistula
6. Relaparotomy for bleeding
7. Small bowel obstruction
8. Cerebrovascular disease
9. Operative mortality
INTERVAL DEBULKING SURGERY
Interval debulking surgery is a cytoreductive surgery following 
induction  chemotherapy  (neoadjuvant  chemotherapy).  Procedure 
done here is same as primary cytoreductive surgery.
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NEOADJUVANT CHEMOTHERAPY   
Neoadjuvant  chemotherapy  represents  any  cytototoxic  drug 
given  prior  to  surgery.  Drug is  admistered  soon  after  histological  
confirmation of ovarian cancer.                       
Treating  the  patients  prior  to  surgery  has  three  theoretical 
advantages :                               
1. Patients  performance  status  is  improved  prior  to  surgery 
owing to reduction in tumour  volume,  ascites  and pleural 
effusion and improvement in oral intake. 
2. Reduction  in  tumour  volume  may  allow  a  less  extensive 
surgery, hence decreasing perioperative morbitity 
3. Finally  surgical  reduction  may  be  improved  which inturn 
leads to better prognosis and survival.  
CHEMOTHERAPEUTIC DRUGS: 
Advanced  stage  ovarian  epithelial  cancers  is  a 
chemoresoponsive  tumour.  Platinum compounds  remain  the single 
most active drug in the management of this disease.
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PLATINUM COMPOUNDS:
Cisplatin  is  hydrolysed  intracellularly  to  produce  a  highly 
active  moiety  which  causes  cross  linking  of  DNA.  It  is  highly 
emetic.  It  causes  damage  to  kidneys,vestibulo  cochlear  apparatus 
and peripheral  nerve.  Antiemetic  drugs  are  routinely  administered 
before  infusing  it.  Renal  toxicity  can  be  reduced  by  maintaining 
good hydration.                                                                       
Carboplatin is a second generation platinum compound  with 
less  toxic  effects.  Nephrotoxicity.  ototoxicity,  neurotoxicity  are 
low. Thrombocytopenia is the dose limiting toxicity       
ALKYLATING AGENTS  
These  compounds  produce  highly  reactive  carbonium  ion 
intermediates  which  transfer  alkyl  groups  to  cellular 
macromolecules  by  forming  covalent  bonds.  Alkylation  results  in 
cross linking of abnormal base paring of DNA strand.
Cyclophosphamide is transformed into active metamobolites 
in liver  (aldophosphamide,  phosphoramine mustard).  Alopecia and 
haemorrhagic cystitis are the prominent side effects 
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Ifophamide,  thiotepa  are  the  other  alkylating  agent  used  in 
ovarian cancer.
TAXANES:
Paclitaxel  is  a  complex  diterpin  taxane.  It  enhances 
polymerization  of  tubulin  ,  abnormal  microtubules  are  produced 
throughout the cell cycle.
Myelosuppression,  glove  and  stocking  neuropathy  are  the 
commonest side effects. Toxicity is reversible. It is dose dependent.
Docetaxel  is another Taxane group of drug. Major toxicity is 
Neutropenia.
ANTITUMOR ANTIMETABOLITES:
It  intercalates  between  DNA  strands  interfering  with  its 
template  function.  Drugs  used  in  this  group  are  Doxorubicin  and 
Mitoxantrane.  The  side  effects  are  cardiomyopathy,  bone  marrow 
depression.
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STANDARD CHEMOTHERAPY REGIMENS:
1.  CISPLATIN                               75 mg / m 2 
      CYCLOPHOSPHAMIDE        750 mg / m2
2.CISPLATIN                                 75 mg / m2 
   PACLITAXEL                             135 mg /m2
3. CARBOPLATIN  - AUC            5-6
   PACLITAXEL                             175 mg / m 2
26
REVIEW OF LITERATURE
                Neoadjuvant Chemotherapy was originally introduced in  
the year 1969 for patients with advanced stage ovarian cancer and 
were  medically  disabled.  Over  the  ensuing  decade  reasonable 
experience  was  obtained  suggesting  that  patients  who  were 
medically unable to tolerate aggressive cytoreductive surgery at the 
time  of  their  initial  presentation,  but  who  received  chemotherapy 
and then were able to undergo cytoreductive surgery, had a survival 
that  was  quite  similar  to  those  patients  who  initially  had  large 
volume disease present  in the upper abdomen or Stage IV disease.  
A decade later,  neoadjuvant  chemotherapy followed by aggressive 
surgery  was  introduced  for  patients  who  are  not  medically 
compromised  but  who,  by  CT  scan  criteria,  appeared  to  have 
disease  that  was  not  surgically  cytoreducible.Basically,  patients 
with disease >2 cm in diameter in the upper abdomen that involved 
coating  the  diaphragm  and  was  confluence  with  implants  in  the 
liver  serosa,  Omentum  replaced  by  tumor  with  the  tumor  in  the 
omentum  reaching  the  hilum  of  spleen,  porta  hepatis  metastasis, 
enlarged (<2 cm) supra-renal  para aortic lymph nodes and disease 
in  the  thorax  were  indications  to  recommend  neoadjuvant 
chemotherapy  as  these  preoperative  CT  findings  were  usually 
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associated with extensive upper abdominal metastasis that could not 
be optimally cytoreduced. 
SVS. Duo  et al (India) conducted a retrospective analysis of  
82  patients  with  advanced  Ovarian  cancers  (Stage  III  & IV)  who 
were  treated  with  NACT  followed  by  surgical  cytoreduction 
between  1995 and 2004.There  were  59  patients  (72%) with  Stage 
III C and 23 patients (28%) with Stage IV disease with a mean age  
of 49.9 years. 27 (32.9%) were premenopausal  while the rest were 
postmenopausal. 
The  median  duration  of  symptoms  was  3  months.  Optimal 
cytoreduction  achieved  in  59  out  of  82  patients  (72%).  In  15 
patients  (18.2%)  had  sub-optimal  cytoreduction  and  in  8  patients 
(9.8%) exploratory laparotomy and closure was performed in view 
of  frozen  pelvis.  Gut  resection  was  required  only  in  6  patients 
(7.3%)  (small  bowel  -3,large  bowel-3).  Mean  hospital  stay  was  4 
days (Range 2-30 days).Post-operative complications occurred in 4 
patients (4.9%) in the form of wound infection in 3 and pancreatic 
fistula in one patient, 5 year survival rate was 32%.
He concluded that a significant number of patients respond to 
NACT leading to higher optimal cytoreduction which may result in 
improved survival.1
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Schim uzu  et  al  conducted  a  comparative  study  in  the 
year  1993  with  138  patients  with  stage  III  and  21  with  Satge  IV 
malignant Ovarian tumor registered during 1969 -1991. 77 patients 
deemed  resectable  received  primary  debulking  followed  by  post-
operative  chemotherapy.  74  patients  received  NACT  and  the 
remaining 8 did not  receive planned NACT, because of  their  poor 
performance  status.Among  the  74  patients  receiving  NACT  34 
(46%)  had  optimal  debulking.  35  patients  among  the  post  –op 
chemotherapy group out of 165 achieved optimal debulking (21%). 
He  concluded  that  optimal  debulking  is  significantly  more  in 
NACT.  2
P Hicher et al, M Mahnar et al studied early response criteria 
and  surgical  outcome  in  patients  with  advanced  epithelial  cancer 
treated  with  NACT.  Response  was monitored  by measuring  target 
lesions,  ascitic  fluidvolume,  CA 125 levels.  The primary outcome 
measure was the preoperative reduction of ascitic fluid volume, CA 
125  level.  Secondary  outcome  measures  were  the  evaluation  of 
residual  tumor  and  perioperative  morbidity  and  mortality.  Any 
amout  of  residual  disease  after  cytoreductive  surgery,  persistant 
ascities,  less pronounced decrease of CA 125 were associated with 
poor progression free survival  rate.  In conclusion he found ascitic 
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fluid  volume  reduction  and  CA  125  decline  appeared  to  be 
appropriate response criteria.27
Tate  et  al  in  the  year  2005  studied  associations  of  CA 125 
regression  rate  with  initial  responses  to  chemotherapy  and 
prognosis. He found out that based on CA 125 regression rate it is  
possible  to  stratify  TIII  C  or  M1 Ovarian  serous  adenocarcinoma 
cases  into those with a  good prognosis  of  survival  and those with 
poor prognosis. Regression coefficient of CA125 level greater than 
-0.039  predicts  good  3  year  survival  after  subsequent  radical 
surgeries.3
Goto et al, Takeno M et al investigated P16INK4a expression 
by  immunocytochemistry  for  ascites  in  advanced  ovarian  cancer. 
The possibility to predict chemotherapeutic response and prognosis. 
The  immunocytochemical  study  was  performed  on  cytology  of 
ascites obtained from 37 Stage III or stage IV ovarian cancer with 
measurable  disease  before  Platinum/Taxane  based  first  line 
chemotherapy  following  primary  cytoreductive  surgery  or  NACT. 
21  of  21  responder  (100%)  and  6  of  16  (44%)  non  responder 
showed  P16INK4a  immunopositivity.  Their  data  suggest  that 
P16INK4a expression of cytology in ascites  is  a candidate  marker 
in prediction of primary response to chemotherapy and prognosis. 4
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Safra  et  al,  Menezer  et  al  evaluated  safety  and  outcome  of 
weekly Carboplatin and Paclitaxel  as  initial  post-op chemotherapy 
for  epithelial  ovarian cancer.  Intravenous Carboplatin AUC=2 and 
Paclitaxel  80 mg/m2 were administered on days 1,8 and 15th of a 
28  day  cycle  for  6-8  cycles.  Study  results  are:  64  women  were 
enrolled with an median age of 65 years. 56 of them (87.6%) were 
diagnosed with stage III & IV. Neutropenia was the most common 
hematological  toxicity.  25%  of  subjects  had  grade  III  to  IV 
neutropenia.  89  % of  the  patients  had  Grade  I  alopecia  and  7.1% 
had Grade  II  alopecia,7.8% had grade  III  fatigue  ,3.1%had Grade 
III neuropathy. Median progression free survival was 25.74 months.  
They concluded that  weekly Carboplatin and Paclitaxel  is  a initial 
Chemotherapy for  epithelial  Ovarian cancer  is a  feasible  and well 
tolerated  regimen  and  should  be  evaluated  in  a  larger  phase  III  
study.5
Vergote et  al,  De wever  et  al  conducted  a  study in the year 
1998 found out that if total metastatic load was more than 1000gms 
prior to debulking surgery had poor survival despite cytoreduction 
to no or less than 1 gm of total residual tumor load.7
Giannopoulos  et  al  conducted a  non randomized  prospective 
cohort  study  of  35  patients  who  underwent  IDS  and  29  patients 
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treated with PDS were included. All patients had Stage III C or IV 
based  on  pre-operative  computed  tomography  findings  or 
laparascopy. All patients were operated by the same lead surgeons 
and received same regimen of chemotherapy. Median intraoperative 
blood  loss,  the  incidence  of  pelvic  lymphadenectomies,  median 
hospital stay and the possibility of admission to intensive care unit  
were  significantly  less  in  IDS group .  He  concluded  that  IDS for 
advanced  ovarian  cancer  may  be  associated  with  less  morbidity 
compared to PDS and appears to require less hospital resources. 8
Houjy  et  al  compared  the  survival  and  perioperative 
morbidities  of  patients  with   advanced  ovarian  cancer  treated  by 
NACT followed IDS or primary cytoreductive surgery followed by 
adjuvant chemotherapy. He found NACT patients had significantly 
less  intraoperative  blood  loss,operative  time,unit  of  blood 
transfusion  and  shorter  hospital  stay.Optimal  cytoreduction  was 
achieved in 95% of NACT patients.9
Kang et al,Nam BH et al analysed (meta analysis) 21 studies 
regarding neoadjuvant chemotherapy in advanced ovarian epithelial 
cancer to determine whether NACT can improve the rate of optimal 
cytoreduction.  Metaanalysis   showed  that  NACT  helped  gynaec 
oncologists achieve an increased rate of optimal cytoreduction. 10
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Chan YM et al studied quality of life with advanced ovarian 
cancer  treated  with  NACT.  Patients  QOL studied  over  time  using 
European  organization  for  research  and treatment  of  cancer  ,QOL 
quiessionaire  c30 and compared  with  that  of  patients  treated  with 
conventional  treatment.  Conclusion  in  the  study  was  QOL  and 
functional status improved after NACT.12
Tangjitgamol  et  al  assessed  the  effectiveness  and 
complication of IDS in patients with advanced stage ovarian cancer. 
They  searched  the  Cochrane  central  register  of  controlled  trials 
(central),  (The  Cochrane  Library,  issue  2,2008),  MEDLINE  (jan 
1966  to  june  2008),  EMBASE  (jan  1966  to  june  2008)   and 
reference  lists  of  included  studies.  Two  review  authors 
independently  assessed  trial  and  extracted  data.  Searches  for 
additional information from study were attempted. Metaanalysis of 
overall  and  progression  free  survival  was  performed  using  fixed 
effects  models.  No  conclusive  evidence  was  found  to  determine 
whether  IDS  between  cycles  of  chemotherapy  would  improve  or 
decrease  survival  rates  of  woman  with  advanced  ovarian  cancer 
compared  with  conventional  treatment.  IDS  appeared  to  yield 
benefit  only  in  the  patients  whose  primary  surgery  was  not 
performed by gynaec oncologists or less extensive.11
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Le  T  et  al  61  patients  who  have  undergone  IDS  following 
NACT.All  surgeries  performed  after  3  cycles  of  Platinum /  Taxol 
combination  chemotherapy.80%  had  a  residual  disease  status  of 
2cm or  less  after  surgery.  Suboptimal  debulking  was  statistically 
associated with tumour involvement of upper abdominal organs and 
non  –normalisation  CA  -125  before  surgery.  The  cox  regression 
modelling identified the microscopic  tumour  residual  status as  the 
only  significant  predictor  of  progression  free  interval.  The 
estimated  mean  survival  for  the  group  was  41.7  months.  NACT 
with  IDS  appeared  safe  and  feasible  in  patients  with  metastatic 
disease.15
Suprasert et  al  reviewed 29 patients retrospectively who have 
undergone  IDS  following  NACT.  Most  had  stage  3c  serous 
cystadenoma carcinoma. Progression free overall survival was 25%. 
Multivariate  analysis  showed  that  a  suboptimal  residual  tumour 
volume  was  statistically  significant  adverse  prognostic  factor  for 
overall  survival.  In  conclusion,  IDS  and  NACT  before 
cytoreductive  surgery  lead  to  a  more  favorable  outcome  with 
advanced epithelial cancer.26
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AIM OF THE STUDY
The Aim is to study the tumor clearance effect of neoadjuvant 
chemotherapy  in  advanced  ovarian  tumor  in  terms  of  optimal 
debulking,  ascitic  fluid  volume  reduction,blood  transfusion 
requirements and to  compare it  with those  who have not  received 
neoadjuvant chemotherapy
STUDY
Prospective study
SETTING
Patients with advanced ovarian tumor admitted in Institute of 
Social  Obstetrics,  Triplicane,  Chennai-5  from  July  2008  to  Dec 
2009 were included in the study.
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MATERIALS 
INCLUSION CRITERIA
•Patients with advanced epithelial ovarian tumor (stage 3 & 4).
•No previous Chemotherapy.
•No Previous Surgery for the same complaint.
•Willing  to  take  neoadjuvant  Chemotherapy and then follow it  up 
with surgery.
EXCLUSION CRITERIA
•Early stage epithelial ovarian tumor (Stage 1 & 2).
•Borderline tumor.
•Non-epithelial ovarian tumor.
•Those who were treated with some form of Oncotherapy.
•Not willing to wait for surgery following CT.
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METHODOLOGY
All patients enrolled in the study will undergo detailed physical 
examination,  routine  hematological,  biochemical  investigations, 
Ultrasound and CT Scan.
For those patients with ascites, ascitic fluid sent for cytology.
If  Cytology report  cofirms that  it  is  Epithelial  ovarian  tumor. 
Patient  receives  Neoadjuvant  chemotherapy  of  Cisplatin  75mg/sq. 
m, Cyclophosphamide 750mg/sq. m for 3 cycles – 6 weeks
After 6 weeks, undergo interval debulking surgery
Optimal Debulking,Ascitic fluid volume,Blood transfusion rate 
are compared with the control group. 
Control  group  in  this  study  will  be  those  patients  with 
advanced  epithelial  tumor  who  have  not  received  neoadjuvant 
chemotherapy and undergone primary cytoreductive surgery in the 
past in Institute of Social Obstetrics, Triplicane, Chennai – 5
The results were analysed  using  Chi-Square  tests.
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 AGE
Age PDS NACT / IDS Percentage
<55 yrs 8 12 40%
> 55 yrs 17 13 60%
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MENOPAUSAL STATUS
Menopause PDS NACT / IDS Percentage
Attained 21 23 88%
Not attained 4 2 12%
MENOPAUSAL STATUS
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HISTOLOGICAL DIAGNOSIS
Histological 
Diagnosis
PDS NACT / IDS Percentage
Serous 
Papillary
21 24 90%
Others 4 1 10%
HISTOLOGICAL DIAGNOSIS
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ASCITES
Ascites PDS NACT / IDS
No. Percentag
e
No. Percentage
>500 ml 21 84% 5 20%
< 500 ml 4 16% 20 80%
P Value: 0.000
ASCITES
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RESIDUAL TUMOUR VOLUME
Residual 
Tumour 
Volume
PDS NACT / IDS
No. Percentag
e
No. Percentage
Optimal 
debulking
7 28% 19 76%
Sub optimal 
debulking
12 48% 4 16%
Open  and 
close
6 24% 2 8%
P Value: 0.002
RESIDUAL TUMOUR VOLUME
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BLOOD TRANSFUSION
Blood 
Transfusion
PDS NACT / IDS
No. Percentag
e
No. Percentage
No 
Transfusion
6 24% 19 76%
≥ 1 unit 
transfusion
19 76% 6 24%
P Value: 0.000
BLOOD TRANSFUSION
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ADHESIONS
Adhesions PDS NACT / IDS
No. Percentag
e
No. Percentage
Present 19 76% 6 24%
Absent 6 24% 19 76%
P Value: 0.000
ADHESIONS
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INJURY  TO  ADJACENT  STRUCTURES
Injury to 
Adjacent 
Structures
PDS NACT / IDS
No. Percentag
e
No. Percentage
Present 6 24% 1 4%
Absent 19 76% 24 96%
INJURY  TO  ADJACENT  STRUCTURES
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61
19
24
0
5
10
15
20
25
30
PDS NACT/IDS
TYPE OF SURGERY
N
O
.O
F 
PA
TI
EN
TS
PRESENT ABSENT
HDU STAY
HDU Stay PDS NACT / IDS
No. Percentag
e
No. Percentage
Present 12 48% 6 24%
Absent 13 52% 19 76%
HDU STAY
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POST OPERATIVE COMPLICATIONS
Post 
Operative 
Complicatio
ns
PDS NACT / IDS
No. Percentag
e
No. Percentage
Present 8 32% 3 12%
Absent 17 68% 22 88%
POST OPERATIVE COMPLICATIONS
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DURATION OF HOSPITAL STAY
Duration of 
Hospital 
Stay
PDS NACT / IDS
No. Percentag
e
No. Percentage
<10 days 15 60% 21 84%
> 10 days 10 40% 4 16%
DURATION OF HOSPITAL STAY
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POST OPERATIVE  COMPLICATIONS
Wound Infection 4
Cardiopulmonary Complication 3
Paralytic Ileus 2
Would Dehiscence 1
Deep  Vein Thrombosis 1
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INJURY TO ADJACENT STRUCTURES
Bladder Injuries 2
Small Bowel Injuries 2
Ureteric Injury 1
Sigmoid colon injury 1
Rectal injury 1
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DISCUSSION
In our  study the range of  age  is  from 40 to 70 years  with a 
median   age  of  55  years.  Devita  et  al  reported  that  increased 
incidence occurs between 60-70 years.13 Reechia et al  in his study 
found that median age for ovarian cancer was 61 years. 14 The range 
was 52-73 years.
 Most  of  the women were postmenopausal  (44 cases-88%)in 
ou  study.  Tien  Le  et  al  in  his  study  reported  that  81  %  were 
postmenopausal15 at the time of diagnosis. 
Novak’s  et  al  reported  that  75  %  of  epithelial  cancers  are 
serous  papillary  carcinomas,16 but  in  our  study   serous  papillary 
carcinomas  was  the  most  common  type  carcinomas  in  45  cases 
(90%). 
Hacker  et  al  reported that  patients  with extensive metastasis 
or massive ascitis before cytoreduction had a poor prognosis even if 
the  patient  was  cytoreduced  to  an  optimal  status.  17 In  addition 
Heinz et al noted that a diameter of largest metastasis and presence 
of  ascitis  before cytoreduction influenced survival.  18 In our study 
ascitic  fluid  was  present  in  21  cases  in  PDS group  (84%),  and  it  
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was present only in 5 cases (20%) of  NACT / IDS group at the time 
of surgery.
Adhesions was present in 19 cases (76%) in PDS group but it 
was seen only in 6 cases (24%) in NACT /IDS group at the time of 
surgery in our study.
In  our  study,  injury  to  adjacent  structures  was  present  in  6 
cases of PDS group (24%) whereas only 1 case in NACT had injury.  
Out  of  the total  7 cases,  2  had bladder  injury,  2 had injury to the 
small bowel, one had ureteric injury, one had sigmoid colon and the 
other had rectal injury. 
12  cases  of  PDS  group  were  admitted  in  High  Dependency 
Unit  whereas  only  6  cases  of  NACT/IDS group  were  admitted  in 
HDU in our study.
Post –op complications were present in 8 cases of PDS group 
(32%), 3 cases (12%) of NACT/IDS group in our study.
Post-op complications noted are: 
1.Wound infection – 4
2. Cardiopulmonary Complication -3 
3. Paralytic ileus -2
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4. Wound dehiscence -1
5. Deep vein thrombosis-1
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In  PDS group,  10  cases  (40%) stayed more  than 10 days  in 
hospital  but  in  NACT/IDS group  only  4  cases  (16%)  admitted  in 
hospital for more than 10 days.  
Schwartz et al.,  Surwit E., et al., in their study reported that 
NACT can   decrease   tumour  volume  and  increase   resectability. 
Patients  may have  less intraoperative  blood loss, shorter operative 
time, less ICU admission and shorter hospital stay.  19&21
Maurice et al.,  have shown the rate of bowel resection, large 
peritoneal   resection  and  post  operative  morbidity  and  mortality 
were  significantly  reduced  in   NACT  group  as  compared    to 
primary           surgery.  22
Kayikclogluf.,  et  al.,  in  his  study 2001 quoted   that  optimal 
cyto reduction is significantly higher in  NACT  group. (p<0.001)  20
Kuhn  et  al.,  in his study  reported the  resection  rate  in the 
group receiving NACT was significantly higher (p=0.04) than that 
of conventional  group.
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In our study, optimal cytoreductive debulking that is , no gross 
residual
disease to less than 2 cms residual disease was achieved in 7 cases 
(28%) out of 25 cases in PDS group, 19 cases (76%) out of 25 cases 
in NACT/IDS group.
Suboptimal  cytoreduction  that  is,  gross  residual  disease  to 
residual 
disease  more  than  2  cms  was  present  in  12  cases  (48%)  of  PDS 
group and 4 cases (16%) of NACT/IDS group.
Laparotomy and closure due to  frozen pelvis  done in  6 cases 
(24%) of 
PDS group and 2 cases (8%) of NACT/IDS group. 
Schimizu et al in his study reported that 35 cases (21%) out of 
165   
acheived optimal cytoreduction in PDS group, 34 cases (46%) out 
of 74 
cases had optimal cytoreduction in NACT/IDS group 2.
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Deo et  al in his study reported that  59 cases (72%) out of 82 
cases 
achieved optimal  cytoreduction,  15 cases  (18.2%) out  of  82  cases 
achieved
suboptimal  cytoreduction  and  8  cases  (9.8)  out  of  82  cases 
exploratory laprotomy and closure was performed. 1
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CONCLUSION
Neo  adjuvant  chemotherapy  is  significantly  more  effective  in 
achieving optimal cytoreduction and reducing ascitic fluid volume 
in advanced ovarian cancer.
Blood  transfusion  requirement  is  significantly  less  in  neo 
adjuvant chemotherapy group.
        Adhesions  are found to be significantly less in NACT group.
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 PROFORMA
Name                Age       Sex      I.P. No.  S.E.Class
Address
Complaints 
     Mass abdomen
       Abdominal distension
         Loss of weight
         Loss of appetite
         Abdominal pain
         Altered bowel habits           
   Menstrual history
          Cycles
          Flow
          LMP
          Attained menopause       Yes        No
   Marital history        Married         Unmarried
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   Obstetric history     Para      Live     Abortion
Drug history 
     H/O oral pills intake
     H/O clomiphene intake
Personal history
     Smoking         Yes                No
     Alcohol           Yes                No 
Family history
      H/0 breast cancer in the family     Yes      No
      H/O ovarian cancer in the family  Yes      No
GENERAL EXAMINATION
                                               Yes         No
         Anemia
         Jaundice
         Pedal edema
         Enlarged cervical glands
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Enlarged Inguinal glands
Per abdomen
           Ascites
            Mass
                     size
                     consistency
                     tenderness
                     mobility
    Per Vaginal examination
             Mass felt or not
             Pouch of Douglas deposits      Yes    No
    Per Rectal examination
INVESTIGATIONS
        Haemogram
        Renal function tests
        Liver function tests
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        Ultrasound pelvis and abdomen
        CT Scan pelvis and abdomen
        X ray Chest – PA view
        Examination under anaesthesia
        Aspiration of ascitic fluid / FNAC / Biopsy                  
TREATMENT
           Neoadjuvant chemotherapy     
                     Drug                  Dose
           Interval Debulking surgery Yes No
 Primary  Cytoreductive surgery Yes No
Per operative findings
          Adhesions
          Ascitic fluid amount
       Ovary 
    Right       Mass size
                                   Consistency
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                         Left         Mass size
Consistency      
Uterus
         Fallopian tubes
          Pouch of douglas
           Omentum
           Peritoneum
           Liver
           Retroperitoneal nodes
Volume of tumour left behind
Blood Transfusion
HDU admission 
Post op complication
Duration of hospital stay
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